MedTrace Logo

Open Label Dose-Finding Study of TRC105 Plus Capecitabine for Metastatic Breast Cancer

NCT01326481 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 19

Last updated 2019-03-18

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine the recommended phase 2 dose and overall safety and tolerability of TRC105 when given in combination with capecitabine for the treatment of patients with progressive or recurrent metastatic breast cancer.

Conditions

Interventions

DRUG

TRC105

IV

DRUG

Capecitabine

oral

Sponsors & Collaborators

  • Roswell Park Cancer Institute

    collaborator OTHER

  • United States Department of Defense

    collaborator FED

  • Tracon Pharmaceuticals Inc.

    lead INDUSTRY

Principal Investigators

  • Charles Theuer, MD PhD · Tracon Pharmaceuticals Inc.

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
120 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-06-30
Primary Completion
2014-09-30
Completion
2014-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01326481 on ClinicalTrials.gov